Jarushka Naidoo: ESMO24 Lung mini-orals

Jarushka Naidoo shared on X:

“ESMO24 Lung mini-orals.

Randomised phase II trial of inhaled corticosteroids in stage III NSCLC treated with cCRT, to reduce radiation pneumonitis:

– 292 patients
– 15% reduction in RP
– no long-term steroid tox

No need for phase III, could do tomorrow.”

Source: Jarushka Naidoo/X

More posts featuring Jarushka Naidoo and ESMO24 on oncodaily.com

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.

She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.